1819.1000 -17.50 (-0.95%)
NSE May 06, 2025 15:31 PM
Volume: 1.4M
 

1819.10
-0.95%
Emkay
contribution of other operational income or other income to the overall numbers. The beat on revenue was driven by a stronger-than-expected India business (revenue of Rs21.5bn was higher by ~8% v/s estimates) as well as US geography (standalone revenue of US$225mn, which reflects a growth of 17% qoq). Q1FY19 clearly benefitted from the launch of AG of gWelchol, plus the impact of supplies normalizing from Halol. However, SUNP remains emphatic that qoq growth was a factor of both and therefore there is no channel filling on account of Halol normalizing. In other words, it means that the...
Sun Pharmaceutical I.. has an average target of 2054.00 from 8 brokers.
More from Sun Pharmaceutical Industries Ltd.
Recommended